Health · 1 sources covering this

STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug

Ahead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist for the rare disease drug.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·2h ago
STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
Ahead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist for the rare disease drug.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/2903ad25f27d40e11ff71599a08877c0cf265223"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Ahead of hearing, FDA questions the efficacy of Capricor&#8217;s Duchenne drug"></iframe>

STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug

How 1 sources are covering this

STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug

More from Health

STAT+: Sarepta names Michael Severino, former Tessera CEO, as new chief executive

STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more

A trend that isn’t fading, ultra-processed baby foods

STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: Ahead of hearing, FDA questions the efficacy of Capricor&#8217;s Duchenne drug

More from Health

STAT+: Sarepta names Michael Severino, former Tessera CEO, as new chief executive

STAT+: Pharmalittle: We&#8217;re reading about a U.S. peptide panel&#8217;s votes, Amgen scuffling with the FDA, and more

A trend that isn&#8217;t fading, ultra-processed baby foods

STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease

Reader

Trust & legal

Across the network

STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug

STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more

A trend that isn’t fading, ultra-processed baby foods